Literature DB >> 24080022

Increased prevalence of autoimmune phenomena in myelofibrosis: relationship with clinical and morphological characteristics, and with immunoregulatory cytokine patterns.

Wilma Barcellini1, Alessandra Iurlo, Tommaso Radice, Francesca Guia Imperiali, Anna Zaninoni, Bruno Fattizzo, Francesca Guidotti, Paola Bianchi, Elisa Fermo, Dario Consonni, Agostino Cortelezzi.   

Abstract

Autoimmune phenomena and cytokines were investigated in 100 patients with myelofibrosis (MF) and related to marrow fibrosis and clinical risk. Anti-erythrocyte antibodies by mitogen-stimulated direct antiglobulin test (MS-DAT) were positive in 45%, anti-platelets in 15% and organ/non organ-specific in 57% of cases, without clinically overt disease, and mostly in low-risk/intermediate-risk-1 and MF-0/MF-1. TGF-β and IL-8 were increased in MS-DAT positive cases, and IFN-γ in patients with serological autoantibodies. TGF-β and IL-17 were elevated in early clinical and morphological stages, while IL-8 increased in advanced stages. These data suggest that autoimmune phenomena and cytokine disregulation are particularly relevant in early MF.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Autoimmunity; Cytokines; Myelofibrosis

Mesh:

Substances:

Year:  2013        PMID: 24080022     DOI: 10.1016/j.leukres.2013.09.001

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  17 in total

Review 1.  Immunological Consequences of JAK Inhibition: Friend or Foe?

Authors:  Donal P McLornan; Alesia A Khan; Claire N Harrison
Journal:  Curr Hematol Malig Rep       Date:  2015-12       Impact factor: 3.952

2.  Pitfalls in the diagnosis of autoimmune haemolytic anaemia.

Authors:  Wilma Barcellini
Journal:  Blood Transfus       Date:  2015-01       Impact factor: 3.443

Review 3.  An immune dysregulation in MPN.

Authors:  Giovanni Barosi
Journal:  Curr Hematol Malig Rep       Date:  2014-12       Impact factor: 3.952

4.  Age-Related Macular Degeneration in Patients With Chronic Myeloproliferative Neoplasms.

Authors:  Marie Bak; Torben Lykke Sørensen; Esben Meulengracht Flachs; Ann-Dorthe Zwisler; Knud Juel; Henrik Frederiksen; Hans Carl Hasselbalch
Journal:  JAMA Ophthalmol       Date:  2017-08-01       Impact factor: 7.389

5.  Primary autoimmune myelofibrosis: a case report and review of the literature.

Authors:  Yasmin Abaza; C Cameron Yin; Carlos E Bueso-Ramos; Sa A Wang; Srdan Verstovsek
Journal:  Int J Hematol       Date:  2016-11-09       Impact factor: 2.490

6.  Activation of non-canonical TGF-β1 signaling indicates an autoimmune mechanism for bone marrow fibrosis in primary myelofibrosis.

Authors:  Fiorella Ciaffoni; Elena Cassella; Lilian Varricchio; Margherita Massa; Giovanni Barosi; Anna Rita Migliaccio
Journal:  Blood Cells Mol Dis       Date:  2015-01-15       Impact factor: 3.039

7.  Impact of Anti-Endothelial Cell Antibodies (AECAs) in Patients with Polycythemia Vera and Thrombosis.

Authors:  Rossella Cacciola; Elio Gentilini Cacciola; Veronica Vecchio; Emma Cacciola
Journal:  Diagnostics (Basel)       Date:  2022-04-25

8.  Autoimmune Myelofibrosis in Systemic Lupus Erythematosus Report of Two Cases and Review of the Literature.

Authors:  Prasad R Koduri; Mohammad Parvez; Sashidhar Kaza; S Vanajakshi
Journal:  Indian J Hematol Blood Transfus       Date:  2015-02-15       Impact factor: 0.900

9.  Bone Marrow Soluble Mediator Signatures of Patients With Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.

Authors:  Juçara Gastaldi Cominal; Maira da Costa Cacemiro; Maria Gabriela Berzoti-Coelho; Illy Enne Gomes Pereira; Fabiani Gai Frantz; Elizabeth Xisto Souto; Dimas Tadeu Covas; Lorena Lobo de Figueiredo-Pontes; Maria Carolina Oliveira; Kelen Cristina Ribeiro Malmegrim; Fabíola Attié de Castro
Journal:  Front Oncol       Date:  2021-05-18       Impact factor: 6.244

10.  Immune derangements in patients with myelofibrosis: the role of Treg, Th17, and sIL2Rα.

Authors:  Jen C Wang; Hemant Sindhu; Chi Chen; Ajay Kundra; Muhammad I Kafeel; Ching Wong; Stephen Lichter
Journal:  PLoS One       Date:  2015-03-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.